Switzerland’s drug approval process lags behind Europe
According to a recent study, medicines are approved on average 249 days later in Switzerland than by the European Medicines Agency (EMA).
The Swiss pharmaceutical association Interpharma said this means that access to vital medicines is becoming increasingly difficult.
The benchmarking study conducted by the pharmaceutical industry and the Swiss Agency for Therapeutic Products, Swissmedic, reveals that companies are submitting their applications later in Switzerland compared to Europe, and that the duration of the review process has also increased, Interpharma announced on Wednesday.
More
What’s behind Switzerland’s push for drug-pricing secrecy?
On average, a drug is approved in Switzerland 249 days later than by the EMA, which represents a 48% increase compared to the previous year. Companies submitted their applications for authorisation to Swissmedic 244 days later than to the EMA.
Interpharma attributes this to the poor framework conditions in Switzerland, which have caused the Swiss market to receive progressively less priority.
Translated from German by DeepL/sp
This news story has been written and carefully fact-checked by an external editorial team. At SWI swissinfo.ch we select the most relevant news for an international audience and use automatic translation tools such as DeepL to translate it into English. Providing you with automatically translated news gives us the time to write more in-depth articles.
If you want to know more about how we work, have a look here, if you want to learn more about how we use technology, click here, and if you have feedback on this news story please write to english@swissinfo.ch.
External Content
Your subscription could not be saved. Please try again.
Almost finished… We need to confirm your email address. To complete the subscription process, please click the link in the email we just sent you.
In compliance with the JTI standards
More: SWI swissinfo.ch certified by the Journalism Trust Initiative
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.